Skip to content

Ketamine for depression: all studies

Page 84 of 154: studies 831 to 840 of 1,534, newest first. Back to the ketamine for depression overview

Research

How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major Depression.

Journal of Psychiatric Practice March 1, 2024 Sheldon H. Preskorn

This column focuses on the status of intravenous racemic ketamine for the treatment of patients suffering from a form of major depressive disorder that does not respond to trials of currently available biogenic amine antidepressants. To provide context, the column reviews the 3 pivotal elements of the usual Food and Drug Administration (FDA) drug approval process: (1) the unmet medical need...

DOI: 10.1097/PRA.0000000000000768 (opens in new tab) Full text (opens in new tab) Ketamine therapy Depression treatment FDA Drug Approval Psychiatric medicine +1

A Comparison of the Efficacy and Adverse Effects of Ketamine and Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: A Systematic Review.

Cureus March 1, 2024 Shaan I Chaudhri, Amina Amin, Binay K Panjiyar et al. 2 citations

Ketamine has been repeatedly demonstrated to be an effective treatment in the management of patients with treatment-resistant depression (TRD). An important question is whether it is equally or more effective than the current gold standard of electroconvulsive therapy (ECT), as the adverse effects of ECT can lead to memory loss and neurocognitive deficits. A literature search was conducted for...

DOI: 10.7759/cureus.55596 (opens in new tab) Full text (opens in new tab) Treatment of trd Treatment-resistant depression trd Therapy-resistant depression Refractory depression +4

Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers.

Scientific Reports February 24, 2024 Jennifer W. Evans, Morgan C Graves, Allison C. Nugent et al. 9 citations

The hippocampus and amygdala have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Preclinical models suggest that stress-related changes in these regions can be reversed by antidepressants, including ketamine. Clinical studies have identified reduced volumes in MDD that are thought to be potentiated by early life stress and worsened by repeated...

Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial

BMC Anesthesiology February 6, 2024 Shurong Li, Zhifang Zhuo, Renwei Li et al.

Background Postpartum depression (PPD) following a cesarean delivery is a frequently seen complication. Despite the prophylactic effects of ketamine, the impact of esketamine on PPD in women undergoing cesarean section remains uncertain. This study aimed to assess the effectiveness of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) in preventing PPD in women...

Anhedonia in bipolar depression treated with ketamine

Bipolar Disorders February 4, 2024 Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska et al. 17 citations

BACKGROUND: Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently,...

DOI: 10.1111/bdi.13409 (opens in new tab) Ketamine Anhedonia Depression economics Bipolar disorder +3

Anti-inflammatory effects of ketamine in the treatment-resistant depression: a narrative review

Farmacja Polska February 3, 2024 Marta Jóźwiak-Bębenista, Paulina Sokołowska, Edward Kowalczyk et al.

Przedmiot badań. U części pacjentów z depresją szczególnie nie odpowiadających na leczenie standardowymi lekami przeciwdepresyjnymi lub z myślami bądź próbami samobójczymi, stan zapalny jako źródło cytokin, przyczynia się do braku odpowiedzi na zastosowane terapie. Szansą dla takich osób jest terapia przy pomocy ketaminy. S-ketamina to szybko działający lek przeciwdepresyjny o wysokiej...

Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis

Frontiers in Psychiatry February 1, 2024 Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco et al. 28 citations

Background Unipolar and bipolar depression present treatment challenges, with patients sometimes showing limited or no response to standard medications. Ketamine and its enantiomer, esketamine, offer promising alternative treatments that can quickly relieve suicidal thoughts. This Overview of Reviews (OoR) analyzed and synthesized systematic reviews (SRs) with meta-analysis on randomized...

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.

The Australian and New Zealand journal of psychiatry February 1, 2024 Anthony Rodgers, Dilara Bahceci, Christopher G. Davey et al. 8 citations

In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established medicines and we suggest potential solutions. The antidepressant effects of generic racemic ketamine were identified over 20 years ago, but there were insufficient incentives for commercial entities to pursue its registration, or support for...

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus February 1, 2024 Suneeta Kumari, Hassan A Chaudhry, Adam Sagot et al. 13 citations

The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been...

DOI: 10.7759/cureus.53987 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression FDA Approval Nmda receptor antagonist Placebo controlled trials +6

Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

medRxiv Preprint Server January 30, 2024 Lauren N. Swanson, Lila S. Jones, Jose Muñoz Aycart et al. preprint

Objective To evaluate the effectiveness of repeated at-home ketamine treatments for depression, generalized anxiety, and social anxiety and assess safety in terms of adverse effects and tendency towards long-term use.

DOI: 10.1101/2024.01.30.24301798 (opens in new tab) Full text (opens in new tab) Mental health treatment Ketamine therapy Depression & anxiety Treatment efficacy +1